[SCHEDULE 13G/A] Aligos Therapeutics, Inc. SEC Filing

Rhea-AI Filing Summary

Woodline Partners LP, as investment adviser to Woodline Master Fund LP, reports beneficial ownership of 518,300 shares of Aligos Therapeutics Voting Common Stock, representing 9.8% of the class based on 5,314,801 shares outstanding. The Schedule 13G/A shows Woodline holds sole voting and sole dispositive power over the reported shares. The filing includes a certification that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. This disclosure notifies the market of a near-10% passive stake in ALGS.

Positive

• Reporting of a clear, material beneficial ownership position of 518,300 shares in Aligos Therapeutics
• The disclosed stake represents a significant 9.8% of the voting class, providing transparency to the market
• Filing reports sole voting and sole dispositive power over the reported shares, clarifying control rights
• Includes a certification that the shares are held in the ordinary course of business and not to influence control

Negative

• None.

Insights

Financial Analyst

TL;DR: Woodline discloses a near-10% passive stake (518,300 shares) in Aligos, signaling a material ownership position without an intent to influence control.

The Schedule 13G/A identifies a beneficial holding of 518,300 shares, equal to 9.8% of the issued Voting Common Stock using the stated 5,314,801-share base. The filing reports sole voting and dispositive power for the reported shares and includes a certification that holdings are in the ordinary course and not intended to change or influence control. For investors, a sub-10% passive position is material for disclosure purposes and can affect liquidity and shareholder composition without implying activist intent per this filing.

Corporate Governance Expert

TL;DR: The Schedule 13G classification and accompanying certification indicate a passive, disclosed ownership of a sizable stake without declared control intent.

The document is filed as a Schedule 13G/A and includes the required certification that the securities were not acquired to influence issuer control. The reporting person is Woodline Partners LP acting as adviser to the Woodline Master Fund LP, and the signature is provided by the fund's General Counsel & Chief Compliance Officer. The filing therefore meets disclosure requirements for beneficial ownership above the 5% threshold while asserting passive intent.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Aligos Therapeutics, Inc.

(Name of Issuer)

Voting Common Stock, par value $0.0001 per share

(Title of Class of Securities)

01626L204

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 01626L204

1

Names of Reporting Persons

Woodline Partners LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 518,300.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 518,300.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

518,300.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.8 %

12

Type of Reporting Person (See Instructions)

IA, PN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Aligos Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: One Corporate Drive, 2nd Flood, South San Francisco, CA, 94080.
Item 2.
(a)	Name of person filing: This statement is filed by Woodline Partners LP ("Woodline Partners" or the "Reporting Person"), a Delaware limited partnership, and the investment adviser to Woodline Master Fund LP (the "Woodline Fund"), with respect to the shares of voting common stock, par value $0.0001 per share ("Voting Common Stock") of Aligos Therapeutics, Inc. (the "Company") directly held by the Woodline Fund. The filing of this statement should not be construed as an admission that the foregoing persons or the Reporting Person is, for the purposes of the Act, the beneficial owner of the shares of Voting Common Stock reported herein.
(b)	Address or principal business office or, if none, residence: The address of the business office of Woodline Partners is 4 Embarcadero Center, Suite 3450, San Francisco, CA 94111.
(c)	Citizenship: Woodline Partners is a Delaware limited partnership.
(d)	Title of class of securities: Voting Common Stock, par value $0.0001 per share
(e)	CUSIP No.: 01626L204
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: The information required by Item 4(a) is set forth in Row 9 of the cover page for the Reporting Person and is incorporated herein by reference. The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 5,314,801 shares of Voting Common Stock outstanding as of May 1, 2025, as reported in the Company's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025, filed with the Securities and Exchange Commission on May 6, 2025.
(b)	Percent of class: 9.8%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for the Reporting Person and is incorporated herein by reference
	(ii) Shared power to vote or to direct the vote: The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for the Reporting Person and is incorporated herein by reference.
	(iii) Sole power to dispose or to direct the disposition of: The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for the Reporting Person and is incorporated herein by reference.
	(iv) Shared power to dispose or to direct the disposition of: The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for the Reporting Person and is incorporated herein by reference.
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. See Item 2(a).
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Woodline Partners LP

Signature:	/s/ Erin Mullen
Name/Title:	Erin Mullen, General Counsel & Chief Compliance Officer
Date:	08/14/2025

FAQ

How many Aligos (ALGS) shares does Woodline Partners report owning?

Woodline Partners reports beneficial ownership of 518,300 shares of Aligos Therapeutics Voting Common Stock.

What percentage of ALGS does Woodline Partners hold?

The filing states the reported position represents 9.8% of the Voting Common Stock based on 5,314,801 shares outstanding.

Does Woodline Partners have voting control over the reported shares of ALGS?

Yes. The Schedule 13G/A reports sole voting power and sole dispositive power for the 518,300 shares.

Was the stake filed as passive or active for ALGS?

The position was disclosed on a Schedule 13G/A and the filing includes a certification that the securities are held in the ordinary course of business and not to change or influence control.

Who filed the Schedule 13G/A for Aligos (ALGS)?

The filing was made by Woodline Partners LP, as investment adviser to Woodline Master Fund LP, signed by Erin Mullen, General Counsel & Chief Compliance Officer.